Brought to you by 
EA Pharma to co-promote Humira in Japan with AbbVie GK
29 Apr 2020
Executive Summary
Eisai Co. Ltd.'s subsidiary EA Pharma Co. Ltd. received rights to co-promote in Japan AbbVie Inc.'s (through its Japanese subsidiary AbbVie GK) fully human anti-TNF-a monoclonal antibody Humira (adalimumab) for gastrointestinal disease indications including ulcerative colitis, Crohn’s disease, and intestinal Behçet’s disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EA Pharma to co-promote Humira in Japan with AbbVie GK
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice